Skip NavigationSkip to Content
Return Return to Search Results

Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

  1. Author:
    Trabert, B.
    Eldridge, R. C.
    Pfeiffer, R. M.
    Shiels, M. S.
    Kemp, T. J.
    Guillemette, C.
    Hartge, P.
    Sherman, M. E.
    Brinton, L. A.
    Black, A.
    Chaturvedi, A. K.
    Hildesheim, A.
    Berndt, S. I.
    Safaeian, M.
    Pinto, L.
    Wentzensen, N.

  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD. britton.trabert@nih.gov. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD. HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD. Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Quebec (CHUQ) Research Center, Laval University, Faculty of Pharmacy, Quebec, Canada. Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD.
    1. Year: 2017
    2. Date: Feb 1
    3. Epub Date: 11/7/2016
  2. Journal: International Journal of Cancer
    1. 140
    2. 3
    3. Pages: 600-610
  4. Type of Article: Article
  5. ISSN: 0020-7136
  1. Abstract:

    Inflammation is proposed to increase risk of developing endometrial cancer, but few prospective epidemiologic studies have investigated the relationship between circulating inflammation markers and endometrial cancer risk. In a nested case-control study within the PLCO Screening Trial we measured serum levels of 64 inflammation-related biomarkers in 284 incident endometrial cancer cases and 284 matched controls. Using multivariable logistic regression inflammation markers were evaluated individually and combined into a cross-validated inflammation score. Of 64 markers, 22 were associated with endometrial cancer risk at p<0.05 and 17 of 22 markers remained associated after multiple testing corrections. After adjusting for BMI and estradiol, SERPINE1 [quartile(Q)4 vs. Q1 odds ratio (OR) (95% confidence interval (CI)), p-trend = 2.43 (0.94-6.29), 0.03] and VEGFA [2.56 (1.52-4.30), 0.0002] were positively associated with endometrial cancer risk, while CCL3 [0.46 (0.27-0.77), 0.01], IL13 [0.55 (0.33-0.93), 0.01], IL21 [0.52 (0.31-0.87), 0.01], IL1B [0.51 (0.30-0.86), 0.01], and IL23 [0.60 (0.35-1.03), 0.02] were inversely associated with risk. We observed large differences in ORs across BMI-inflammation score categories. Endometrial cancer risk was most pronounced among obese women with the highest inflammation score tertile (T) [10.25 (3.56-29.55) vs. normal BMI/T1]. Several inflammation markers were prospectively associated with endometrial cancer, including adipokines, pro- and anti-inflammatory cytokines, angiogenic factors, and acute phase proteins. Inverse associations with anti-inflammatory markers (IL13, IL21), other inflammation markers/mediators (CCL3, IL1B, IL23), and a robust positive association between VEGFA and endometrial cancer risk were independent of BMI and estradiol, suggesting that these factors may influence risk through other mechanisms. This article is protected by copyright. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/ijc.30478
  3. PMID: 27770434
  4. View record in Web of Science®
  5. WOS: 000390702500012

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel